Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

IONS - Ionis Pharmaceuticals, Inc. So'nggi... | Finranks

Home

IONS

I

Ionis Pharmaceuticals, Inc. (IONS)

NMS – Real vaqt narxi. Valyuta: USD

72.15

-2.09 (-2.82%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

72.15

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?

Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.

Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently trading near $72.70.

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026. "Alexander disease is a devastating condition,.

Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative

Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative

Ionis Pharmaceuticals (IONS) projects $2B+ peak revenue for Olezarsen, but I believe this is highly conservative given the U.S. addressable market. Olezarsen demonstrated a 72% reduction in triglycerides and 85% reduction in acute pancreatitis events, with no comparable competition in efficacy. Current guidance assumes reaching only 10% of the 1M high-risk U.S. sHTG patients, with pricing likely near $20,000 per patient annually.

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript

Videolar

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases

Press-relizlar

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026. "Alexander disease is a devastating condition,.

Ionis announces changes to Board of Directors

Ionis announces changes to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retiring at the end of their term and Peter N. Reikes will be rejoining as a director. The changes will be effective June 4, 2026. Ms. Parshall has served as a director since September 2000. Previously, she served as Ionis' chief operating officer from December 2007 through December 2017 and as chief fina.

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 8-11, 2026) and 5th International Scientific Congress on SMA (SMA Europe 2026; March 11-14, 2026).

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026. “Current standard of care therapies for sHTG provide limited benefit, leaving people vulnerable to recurrent and debilitating acut.